Seema Kazi, MD
Psychiatry · Euless, TXNPI 1780606772
Payments from drug & device makers
Across 371 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$994
- Neurocrine Biosciences, Inc.$802
- AbbVie$648
- Johnson & Johnson$513
- Alkermes, Inc.$502
- Otsuka America Pharmaceutical, Inc.$455
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,16196%
- Education$2994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 76 | $994 |
| Neurocrine Biosciences, Inc. | 36 | $802 |
| AbbVie(2 entities) | 45 | $648 |
| Johnson & Johnson | 19 | $513 |
| Alkermes, Inc. | 23 | $502 |
| Otsuka America Pharmaceutical, Inc. | 26 | $455 |
| Axsome Therapeutics, Inc. | 10 | $409 |
| Validus Pharmaceuticals LLC | 5 | $398 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $375 |
| Teva Pharmaceuticals USA, Inc. | 7 | $357 |
| Lundbeck LLC | 19 | $347 |
| Corium, LLC | 7 | $196 |
| Ironshore Pharmaceuticals Inc. | 9 | $176 |
| E.r. Squibb & Sons, L.L.C. | 9 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $121 |
| Vanda Pharmaceuticals Inc. | 6 | $118 |
| Tris Pharma Inc | 5 | $109 |
| Eisai Inc. | 4 | $94 |
| Noven Therapeutics, LLC | 5 | $89 |
| Supernus Pharmaceuticals, Inc. | 5 | $82 |
| Collegium Pharmaceutical, Inc. | 4 | $67 |
| Orexo US, Inc. | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Boehringer Ingelheim | 2 | $43 |
| Indivior Inc. | 2 | $43 |
| Livanova USA, Inc. | 2 | $41 |
| Merck | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Bausch Health US, LLC | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| Biogen | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,459 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $61,260 |
| SpravatoEsketamine Hcl | 23 | $40,565 |
| RexultiBrexpiprazole | 11 | $24,726 |
| VraylarCariprazine Hcl | 14 | $22,348 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $19,360 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $11,636 |
| Lurasidone Hcl | 46 | $10,240 |
| Lisdexamfetamine Dimesylate | 39 | $9,960 |
| BelsomraSuvorexant | 20 | $9,839 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 191 | $5,981 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 102 | $5,818 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 92 | $5,370 |
| Methylphenidate Er (La)Methylphenidate Hcl | 28 | $4,322 |
| Aripiprazole | 43 | $4,247 |
| Vilazodone Hcl | 35 | $2,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $357 | $61,26011 claims |
| Johnson & JohnsonSpravato | $513 | $40,56523 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $455 | $24,72611 claims |
| AbbVieVraylar | $648 | $22,34814 claims |
| Axsome Therapeutics, Inc.Auvelity | $409 | $19,36018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $121 | $11,63628 claims |
| MerckBelsomra | $34 | $9,83920 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $1,01464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Euless
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.